Racial and socioeconomic disparities in triple-negative breast cancer treatment

References

• Cho B, Han Y, Lian M, et al. Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative breast cancer. JAMA Oncol. 2021;7(7):1016–1023. doi: 10.1001/jamaoncol.2021.1254
   PubMed Web of Science ®Google Scholar
• Ramos Chaves M, Boléo-Tomé C, Monteiro-Grillo I, et al. The diversity of nutritional status in cancer: new insights. Oncology. 2010;15(5):523–530. doi: 10.1634/theoncologist.2009-0283
   Google Scholar
• Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010;60(6):351–375. doi: 10.3322/caac.20082
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Brugioni E, Cathcart-Rake E, Metsker J, et al. Germline BRCA-Mutated HER2-negative advanced breast cancer: overcoming challenges in genetic testing and clinical considerations when using talazoparib. Clin Breast Cancer. 2023;23(5):469–477. doi: 10.1016/j.clbc.2023.04.006
   PubMed Web of Science ®Google Scholar
• Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5–23. doi: 10.1016/j.molonc.2010.11.003
   PubMed Web of Science ®Google Scholar
• Fougner C, Bergholtz H, Norum JH, et al. Re-definition of claudin-low as a breast cancer phenotype. Nat Commun. 2020;11(1):1787. doi: 10.1038/s41467-020-15574-5
   PubMed Web of Science ®Google Scholar
• Prat A, Adamo B, Cheang MCU, et al. Molecular characterization of basal‐like and non‐basal‐like triple‐negative breast cancer. Oncology. 2013;18(2):123–133. doi: 10.1634/theoncologist.2012-0397
   Google Scholar
• Prat A, Karginova O, Parker JS, et al. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat. 2013;142(2):237–255. doi: 10.1007/s10549-013-2743-3
   PubMed Web of Science ®Google Scholar
• Russnes HG, Lingjærde OC, Børresen-Dale A-L, et al. Breast cancer molecular stratification: from intrinsic subtypes to integrative clusters. Am J Pathol. 2017;187(10):2152–2162. doi: 10.1016/j.ajpath.2017.04.022
   PubMed Web of Science ®Google Scholar
• Mrklić I, Pogorelić Z, Ćapkun V, et al. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem. 2013;115(4):344–348. doi: 10.1016/j.acthis.2012.09.006
   PubMed Web of Science ®Google Scholar
• Miyashita M, Ishida T, Ishida K, et al. Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates. Virchows Arch. 2011;458(1):65–72. doi: 10.1007/s00428-010-1009-2
   PubMed Web of Science ®Google Scholar
• Tang P, Tse GM. Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 update. Arch Pathol Lab Med. 2016;140(8):806–814. doi: 10.5858/arpa.2015-0133-RA
   PubMed Web of Science ®Google Scholar
• Bhargava R, Striebel J, Beriwal S, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009;2:444.
   PubMed Web of Science ®Google Scholar
• Kanapathy Pillai SK, Tay A, Nair S, et al. Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clin Pathol. 2012;12(1):1–8. doi: 10.1186/1472-6890-12-18
   PubMedGoogle Scholar
• Sánchez-Muñoz A, Navarro-Perez V, Plata-Fernández Y, et al. Proliferation determined by ki-67 defines different pathologic response to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer. Clin Breast Cancer. 2015;15(5):343–347. doi: 10.1016/j.clbc.2015.01.005
   PubMed Web of Science ®Google Scholar
• He X, Chen Z, Fu T, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014;14(1):1–13. doi: 10.1186/1471-2407-14-153
   PubMedGoogle Scholar
• Salehi F, Agur A, Scheithauer BW, et al. Ki-67 in pituitary neoplasms: a review—part I. Neurosurgery. 2009;65(3):429–437. doi: 10.1227/01.NEU.0000349930.66434.82
   PubMed Web of Science ®Google Scholar
• Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5:2929.
   PubMed Web of Science ®Google Scholar
• Sabatier R, Finetti P, Guille A, et al. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Mol Cancer. 2014;13(1):1–14. doi: 10.1186/1476-4598-13-228
   PubMedGoogle Scholar
• Molyneux G, Geyer FC, Magnay F-A, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell. 2010;7(3):403–417. doi: 10.1016/j.stem.2010.07.010
   PubMed Web of Science ®Google Scholar
• Kumar B, Prasad M, Bhat-Nakshatri P, et al. Normal breast-derived epithelial cells with luminal and intrinsic subtype-enriched gene expression document interindividual differences in their differentiation cascade. Cancer Res. 2018;78(13_Supplement):5107–5107. doi: 10.1158/1538-7445.AM2018-5107
   PubMed Web of Science ®Google Scholar
• Van Laere SJ, Van den Eynden GG, Van der Auwera I, et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat. 2006;95:243–255. doi: 10.1007/s10549-005-9015-9
   PubMed Web of Science ®Google Scholar
• Eroles P, Bosch A, Pérez-Fidalgo JA, et al. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38(6):698–707. doi: 10.1016/j.ctrv.2011.11.005
   PubMed Web of Science ®Google Scholar
• Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9:S73–S81. doi: 10.3816/CBC.2009.s.008
   PubMed Web of Science ®Google Scholar
• Joensuu K, Leidenius M, Kero M, et al. ER, PR, HER2, ki-67 and CK5 in early and late relapsing breast cancer—reduced CK5 expression in metastases. Breast Cancer Basic Clin Res. 2013;7:BCBCR–S10701. doi: 10.4137/BCBCR.S10701
   Google Scholar
• Inic Z, Zegarac M, Inic M, et al. Difference between luminal a and luminal B subtypes according to ki-67, tumor size, and progesterone receptor negativity providing prognostic information. Clin Med Insights Oncol. 2014;8:CMO–S18006. doi: 10.4137/CMO.S18006
   Google Scholar
• Pellegrino B, Hlavata Z, Migali C, et al. Luminal breast cancer: risk of recurrence and tumor-associated immune suppression. Mol Diagn Ther. 2021;25(4):409–424. doi: 10.1007/s40291-021-00525-7
   PubMed Web of Science ®Google Scholar
• Liu D Luminal B breast cancer: what is it? [Internet]. City Hope-Cancer Cent. 2022. Available from: https://www.cancercenter.com/cancer-types/breast-cancer/types/breast-cancer-molecular-types/luminal-b
   Google Scholar
• Frigerio A, Sardanelli F, Podo F, et al. Radiological screening of breast cancer: evolution. Breast Cancer Innov Res Manag. Springer. 2017;171–203.
   Google Scholar
• Aysola K, Desai A, Welch C, et al. Triple negative breast cancer–an overview. Hered Genet Curr Res. 2013;2013:1–3.
   PubMedGoogle Scholar
• Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology (Williston Park). 2008;22(11):1233–9; discussion 1239–1243.
   Web of Science ®Google Scholar
• Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol. 2012;23:vi19–vi22. doi: 10.1093/annonc/mds190
   PubMed Web of Science ®Google Scholar
• Palma G, Frasci G, Chirico A, et al. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget. 2015;6(29):26560. doi: 10.18632/oncotarget.5306
   PubMedGoogle Scholar
• Toss A, Cristofanilli M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res. 2015;17(1):1–11. doi: 10.1186/s13058-015-0560-9
   PubMedGoogle Scholar
• Jhan J-R, Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics. 2017;18(17):1595–1609. doi: 10.2217/pgs-2017-0117
   PubMed Web of Science ®Google Scholar
• Choupani E, Gomari MM, Zanganeh S, et al. Newly developed targeted therapies against the androgen receptor in triple-negative breast cancer: a review. Pharmacol Rev. 2023;75(2):309–327. doi: 10.1124/pharmrev.122.000665
   PubMed Web of Science ®Google Scholar
• Islam R, Lam KW. Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer. Eur J Med Chem. 2020;207:112812. doi: 10.1016/j.ejmech.2020.112812
   PubMed Web of Science ®Google Scholar
• Mooney SM, Talebian V, Jolly MK, et al. The GRHL2/ZEB feedback loop—a key axis in the regulation of EMT in breast cancer. J Cell Biochem. 2017;118(9):2559–2570. doi: 10.1002/jcb.25974
   PubMed Web of Science ®Google Scholar
• Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J. 2021;27(1):8–16. doi: 10.1097/PPO.0000000000000500
   PubMed Web of Science ®Google Scholar
• Thike AA, Cheok PY, Jara-Lazaro AR, et al. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010;23(1):123–133. doi: 10.1038/modpathol.2009.145
   PubMed Web of Science ®Google Scholar
• Voutilainen S, Heikkilä P, Sampo M, et al. Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation, and androgen receptor in metaplastic breast cancer and their prognostic impact. Acta Oncol (Madr). 2021;60(9):1233–1239. doi: 10.1080/0284186X.2021.1950927
   PubMed Web of Science ®Google Scholar
• Pintens S, Neven P, Drijkoningen M, et al. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. J Clin Pathol. 2009;62(7):624–628. doi: 10.1136/jcp.2008.061358
   PubMed Web of Science ®Google Scholar
• Haupt B, Ro JY, Schwartz MR. Basal-like breast carcinoma: a phenotypically distinct entity. Arch Pathol Lab Med. 2010;134(1):130–133. doi: 10.5858/134.1.130
   PubMed Web of Science ®Google Scholar
• Choccalingam C, Rao L, Rao S. Clinico-pathological characteristics of triple negative and non triple negative high grade breast carcinomas with and without basal marker (CK5/6 and EGFR) expression at a rural tertiary hospital in India. Breast Cancer Basic Clin Res. 2012;6:BCBCR–S8611. doi: 10.4137/BCBCR.S8611
   Google Scholar
• Comen E, Davids M, Kirchhoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi women. Breast Cancer Res Treat. 2011;129(1):185–190. doi: 10.1007/s10549-011-1433-2
   PubMed Web of Science ®Google Scholar
• Muendlein A, Rohde BH, Gasser K, et al. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. J Cancer Res Clin Oncol. 2015;141(11):2005–2012. doi: 10.1007/s00432-015-1986-2
   PubMed Web of Science ®Google Scholar
• MD Anderson Cancer Center. Your breast cancer risk: how it’s affected by race [internet]. MD Anderson. 2019 [cited 2023 Oct 3]. Available from: https://www.mdanderson.org/publications/focused-on-health/your-breast-cancer-risk–how-it-s-affected-by-race-.h11-1592991.html
   Google Scholar
• American Cancer Society. Breast cancer facts & figures: 2017-2018 [Internet]. 2017 [cited 2023 Oct 3]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf
   Google Scholar
• Connor CS, Touijer AK, Krishnan L, et al. Local recurrence following breast conservation therapy in African-American women with invasive breast cancer. Am J Surg. 2000;179(1):22–26. doi: 10.1016/S0002-9610(99)00258-5
   PubMed Web of Science ®Google Scholar
• Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541. doi: 10.3322/caac.21754
   PubMed Web of Science ®Google Scholar
• Hunter CP, Redmond CK, Chen VW, et al. Breast cancer: factors associated with stage at diagnosis in black and white women. JNCI J Natl Cancer Inst. 1993;85(14):1129–1137. doi: 10.1093/jnci/85.14.1129
   Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M. SEER cancer statistics review, 1975–2014. Bethesda, MD: National Cancer Institute; 2017 Apr. https://seer.cancer.gov/csr/1975_2014/
   Google Scholar
• Klawiter M. The biopolitics of breast cancer: changing cultures of disease and activism. Minneapolis, Minnesota, USA: University of Minnesota Press; 2008.
   Google Scholar
• du Terrail JO, Leopold A, Joly C, et al. Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer. Nat Med. 2023;29(1):135–146. doi: 10.1038/s41591-022-02155-w
   PubMedGoogle Scholar
• Colditz GA, Bohlke K. Priorities for the primary prevention of breast cancer. CA Cancer J Clin. 2014;64(3):186–194. doi: 10.3322/caac.21225
   PubMed Web of Science ®Google Scholar
• Ball S, Arevalo M, Juarez E, et al. Breast cancer chemoprevention: an update on current practice and opportunities for primary care physicians. Prev Med. 2019;129:105834. doi: 10.1016/j.ypmed.2019.105834
   PubMed Web of Science ®Google Scholar
• Prasad V, Diener-West M, et al. Primary chemoprevention of breast cancer: are the adverse effects too burdensome? CMAJ. 2015;187(9):E276–E278. doi: 10.1503/cmaj.141627
   PubMed Web of Science ®Google Scholar
• Korfage IJ, Fuhrel-Forbis A, Ubel PA, et al. Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. Breast Cancer Res. 2013;15(5):1–9. doi: 10.1186/bcr3468
   Web of Science ®Google Scholar
• Jones T, Guzman A, Silverman T, et al. Perceptions of racially and ethnically diverse women at high risk of breast cancer regarding the use of a web-based decision aid for chemoprevention: qualitative study nested within a randomized controlled trial. J Med Internet Res. 2021;23(6):e23839. doi: 10.2196/23839
   PubMed Web of Science ®Google Scholar
• Elledge RM, Clark GM, Chamness GC, et al. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. JNCI J Natl Cancer Inst. 1994;86(9):705–712. doi: 10.1093/jnci/86.9.705
   Web of Science ®Google Scholar
• Harlan LC, Coates RJ, Block G, et al. Estrogen receptor status and dietary intakes in breast cancer patients. Epidemiology. 1993;4(1):25–31. doi: 10.1097/00001648-199301000-00006
   PubMed Web of Science ®Google Scholar
• Society AC. Cancer Facts & Figures for African American/Black People 2022-2024. Atlanta: American Cancer Society, Inc.; 2022.
   Google Scholar
• Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 2006;295(21):2492–2502. doi: 10.1001/jama.295.21.2492
   PubMed Web of Science ®Google Scholar
• Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer: results of the national cancer institute black/white cancer survival study. JAMA. 1994;272(12):947–954. doi: 10.1001/jama.1994.03520120057031
   PubMed Web of Science ®Google Scholar
• Optenberg SA, Thompson IM, Friedrichs P, et al. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995;274(20):1599–1605. doi: 10.1001/jama.1995.03530200035033
   PubMed Web of Science ®Google Scholar
• BCRF. Understanding Breast Cancer Racial Disparities [Internet]. 2023 [cited 2024 Jan 31]. Available from: https://www.bcrf.org/blog/understanding-breast-cancer-racial-disparities/
   Google Scholar
• Van Ryn M, Burke J. The effect of patient race and socio-economic status on physicians’ perceptions of patients. Soc Sci Med. 2000;50(6):813–828. doi: 10.1016/S0277-9536(99)00338-X
   PubMed Web of Science ®Google Scholar
• Zhang X, Yeung KT. Metastatic Triple-Negative Breast Cancer. Curr Breast Cancer Rep. 2023;15(3):288–297. doi: 10.1007/s12609-023-00493-3
   Web of Science ®Google Scholar
• Andreopoulou E, Kelly CM, McDaid HM. Therapeutic advances and new directions for triple-negative breast cancer. Breast Care. 2017;12(1):20–27. doi: 10.1159/000455821
   Web of Science ®Google Scholar
• Aldrighetti CM, Niemierko A, Van Allen E, et al. Racial and ethnic disparities among participants in precision oncology clinical studies. JAMA Netw Open. 2021;4(11):e2133205. doi: 10.1001/jamanetworkopen.2021.33205
   PubMed Web of Science ®Google Scholar
• Pan J-W, Zabidi MMA, Ng P-S, et al. The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. Nat Commun. 2020;11(1):6433. doi: 10.1038/s41467-020-20173-5
   PubMed Web of Science ®Google Scholar
• Serrano-Gomez SJ, Fejerman L, Zabaleta J. Breast cancer in latinas: a focus on intrinsic subtypes distribution. Cancer Epidemiol Biomarkers Prev. 2018;27(1):3–10. doi: 10.1158/1055-9965.EPI-17-0420
   PubMed Web of Science ®Google Scholar
• Stringer-Reasor EM, May JE, Olariu E, et al. An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. Breast Cancer Res. 2021;23(1):1–12. doi: 10.1186/s13058-021-01408-9
   PubMed Web of Science ®Google Scholar
• Reeder-Hayes K, Hinton SP, Meng K, et al. Disparities in use of human epidermal growth hormone receptor 2–targeted therapy for early-stage breast cancer. J Clin Oncol. 2016;34(17):2003. doi: 10.1200/JCO.2015.65.8716
   PubMed Web of Science ®Google Scholar
• Yedjou CG, Sims JN, Miele L, et al. Health and racial disparity in breast cancer. Breast cancer metastasis drug resist challenges. Prog. 2019;31–49.
   Google Scholar
• Masuda H, Harano K, Miura S, et al. Changes in triple-negative breast cancer molecular subtypes in patients without pathologic complete response after neoadjuvant systemic chemotherapy. JCO Precis Oncol. 2022;6(6):e2000368. doi: 10.1200/PO.20.00368
   PubMedGoogle Scholar
• Li X, Krishnamurti U, Bhattarai S, et al. Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol. 2016;145(6):871–878. doi: 10.1093/ajcp/aqw045
   PubMed Web of Science ®Google Scholar
• Drisis S, Metens T, Ignatiadis M, et al. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy. Eur Radiol. 2016;26(5):1474–1484. doi: 10.1007/s00330-015-3948-0
   PubMed Web of Science ®Google Scholar
• Ma SJ, Serra LM, Yu B, et al. Racial/Ethnic differences and trends in pathologic complete response following neoadjuvant chemotherapy for breast cancer. Cancers (Basel). 2022;14(3):534. doi: 10.3390/cancers14030534
   PubMed Web of Science ®Google Scholar
• Meng M, Wang H, Zaorsky NG, et al. Risk‐adapted stereotactic body radiation therapy for central and ultra‐central early‐stage inoperable non‐small cell lung cancer. Cancer Sci. 2019;110(11):3553–3564. doi: 10.1111/cas.14185
   PubMed Web of Science ®Google Scholar
• Killelea BK, Yang VQ, Wang S-Y, et al. Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the national cancer data base. J Clin Oncol. 2015;33(36):4267–4276. doi: 10.1200/JCO.2015.63.7801
   PubMed Web of Science ®Google Scholar
• Warner ET, V BK, Strand C, et al. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective alliance clinical trials (A151426). Breast Cancer Res Treat. 2016;159(1):109–118. doi: 10.1007/s10549-016-3918-5
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Kau S-W, et al. Triple receptor–negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 2009;27(2):220. doi: 10.1200/JCO.2008.17.9952
   PubMed Web of Science ®Google Scholar
• Chavez‐MacGregor M, Litton J, Chen H, et al. Pathologic complete response in breast cancer patients receiving anthracycline‐and taxane‐based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer. 2010;116(17):4168–4177. doi: 10.1002/cncr.25296
   PubMed Web of Science ®Google Scholar
• Toi M, Lee SJ, Lee ES, et al. Abstract S1-07: a phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Res. 2016;76(4_Supplement):S1–7. doi: 10.1158/1538-7445.SABCS15-S1-07
   Google Scholar
• Zujewski JA, Rubinstein L. CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data. NPJ Breast Cancer. 2017;3(1):27. doi: 10.1038/s41523-017-0029-3
   PubMedGoogle Scholar
• Nandini D, Jennifer A, Pradip D. Therapeutic strategies for metastatic triple-negative breast cancers: from negative to positive. Pharmaceuticals. 2021;14(5):455. doi: 10.3390/ph14050455
   Web of Science ®Google Scholar
• Pilié PG, Gay CM, Byers LA, et al. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019;25(13):3759–3771. doi: 10.1158/1078-0432.CCR-18-0968
   PubMed Web of Science ®Google Scholar
• Tarantino P, Corti C, Schmid P, et al. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer. 2022;8(1):23. doi: 10.1038/s41523-022-00386-1
   PubMed Web of Science ®Google Scholar
• Schmid P, Salgado R, Park YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol. 2020;31(5):569–581. doi: 10.1016/j.annonc.2020.01.072
   PubMed Web of Science ®Google Scholar
• Adams E, Wildiers H, Neven P, et al. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape. ESMO Open. 2021;6(4):100204. doi: 10.1016/j.esmoop.2021.100204
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Sharkey RM. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. Expert Opin Biol Ther. 2020;20(8):871–885. doi: 10.1080/14712598.2020.1757067
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690. doi: 10.1038/nrclinonc.2016.66
   PubMed Web of Science ®Google Scholar
• Deng M, Chen H, Zhu X, et al. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China. Int J Cancer. 2019;145(6):1517–1528. doi: 10.1002/ijc.32184
   PubMed Web of Science ®Google Scholar
• Engel C, Rhiem K, Hahnen E, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. 2018;18(1):1–6. doi: 10.1186/s12885-018-4029-y
   PubMedGoogle Scholar
• Latif F, Bint Abdul Jabbar H, Malik H, et al. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Expert Rev Anticancer Ther. 2022;22(2):229–235. doi: 10.1080/14737140.2022.2023011
   PubMed Web of Science ®Google Scholar
• Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: a SEER (surveillance, epidemiology, and end results) program population-based study. Arch Intern Med. 2002;162(17):1985–1993. doi: 10.1001/archinte.162.17.1985
   PubMed Web of Science ®Google Scholar
• Compton MT, Shim RS. The social determinants of mental health. Focus (Madison). 2015;13(4):419–425. doi: 10.1176/appi.focus.20150017
   Google Scholar
• Alhusen JL, Bower KM, Epstein E, et al. Racial discrimination and adverse birth outcomes: an integrative review. J Midwifery Womens Health. 2016;61(6):707–720. doi: 10.1111/jmwh.12490
   PubMed Web of Science ®Google Scholar
• Zhang W, Bai Y, Sun C, et al. Racial and regional disparities of triple negative breast cancer incidence rates in the United States: an analysis of 2011–2019 NPCR and SEER incidence data. Front Public Health. 2022;10:1058722. doi: 10.3389/fpubh.2022.1058722
   PubMed Web of Science ®Google Scholar
• Benefield HC, Reeder-Hayes KE, Nichols HB, et al. Outcomes of hormone-receptor positive, HER2-negative breast cancers by race and tumor biological features. JNCI Cancer Spectr. 2021;5(1):kaa072. doi: 10.1093/jncics/pkaa072
   Web of Science ®Google Scholar
• Wang F, Zheng W, Bailey CE, et al. Racial/Ethnic disparities in all-cause mortality among patients diagnosed with triple-negative breast cancer. Cancer Res. 2021;81(4):1163–1170. doi: 10.1158/0008-5472.CAN-20-3094
   PubMed Web of Science ®Google Scholar
• Goel N, Kim DY, Guo JA, et al. Racial differences in genomic profiles of breast cancer. JAMA Netw Open. 2022;5(3):e220573. doi: 10.1001/jamanetworkopen.2022.0573
   PubMed Web of Science ®Google Scholar
• Cohen SY, Stoll CR, Anandarajah A, et al. Modifiable risk factors in women at high risk of breast cancer: a systematic review. Breast Cancer Res. 2023;25(1):1–20. doi: 10.1186/s13058-023-01636-1
   PubMed Web of Science ®Google Scholar
• Stern MC, Fejerman L, Das R, et al. Variability in cancer risk and outcomes within US latinos by national origin and genetic ancestry. Curr Epidemiol Reports. 2016;3(3):181–190. doi: 10.1007/s40471-016-0083-7
   PubMedGoogle Scholar
• Soto AA, Bernal AM, Mesias JA. Abstract P4-03-06: clinical and socioeconomic disparities in treatment and survival between Hispanic and non-Hispanic Black women with non-metastatic triple-negative breast cancer. Cancer Res. 2023;83(5_Supplement):4–3. doi: 10.1158/1538-7445.SABCS22-P4-03-06
   Google Scholar
• Hossain F, Danos D, Prakash O, et al. Neighborhood social determinants of triple negative breast cancer. Front Public Health. 2019;7:18. doi: 10.3389/fpubh.2019.00018
   PubMed Web of Science ®Google Scholar
• Wynn TA, Taylor-Jones MM, Johnson RE, et al. Using community-based participatory approaches to mobilize communities for policy change. Fam Community Heal. 2011;34(Supplement S1):S102–S114. doi: 10.1097/FCH.0b013e318202ee72
   PubMedGoogle Scholar
• AACR. Overcoming disparities through policy | AACR cancer disparities progress report 2020 [internet]. [cited 2023 Aug 9]. Available from: https://cancerprogressreport.aacr.org/disparities/chd20-contents/chd20-overcoming-cancer-health-disparities-through-science-based-public-policy/
   Google Scholar
• NCI launches largest-ever study of breast cancer genetics in black women - NCI [Internet]. [cited 2023 Aug 9]. Available from: https://www.cancer.gov/news-events/press-releases/2016/breast-cancer-genetics-black-women
   Google Scholar
• National Breast and Cervical Cancer Early Detection Program | CDC [Internet]. [cited 2023 Aug 9]. Available from: https://www.cdc.gov/cancer/nbccedp/index.htm
   Google Scholar
• All of us research program | National Institutes of Health (NIH) [Internet]. [cited 2023 Aug 9]. Available from: https://allofus.nih.gov/
   Google Scholar
• Status of state Medicaid expansion decisions: interactive map | KFF [Internet]. [cited 2023 Aug 9]. Available from: https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions-interactive-map/
   Google Scholar
• System-wide changes can help reduce cancer disparities - NCI [Internet]. [cited 2023 Aug 9]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2021/black-white-cancer-disparities-survival-accure
   Google Scholar
• Vives N, Farre A, Ibanez-Sanz G, et al. Text messaging as a tool to improve cancer screening programs (M-TICS study): a randomized controlled trial protocol. PLoS One. 2021;16(1):e0245806. doi: 10.1371/journal.pone.0245806
   PubMed Web of Science ®Google Scholar
• Schliemann D, Tan MM, Hoe WMK, et al. mHealth interventions to improve cancer screening and early detection: scoping review of reviews. J Med Internet Res. 2022;24(8):e36316. doi: 10.2196/36316
   PubMed Web of Science ®Google Scholar